NOVO.B.DK

277.8

-2.22%↓

GMAB.DK

1,540.5

-5.84%↓

HLUNB.DK

44.1

+2.65%↑

ZEAL.DK

301.9

-3.08%↓

AMBUB.DK

64.45

-1.83%↓

NOVO.B.DK

277.8

-2.22%↓

GMAB.DK

1,540.5

-5.84%↓

HLUNB.DK

44.1

+2.65%↑

ZEAL.DK

301.9

-3.08%↓

AMBUB.DK

64.45

-1.83%↓

NOVO.B.DK

277.8

-2.22%↓

GMAB.DK

1,540.5

-5.84%↓

HLUNB.DK

44.1

+2.65%↑

ZEAL.DK

301.9

-3.08%↓

AMBUB.DK

64.45

-1.83%↓

NOVO.B.DK

277.8

-2.22%↓

GMAB.DK

1,540.5

-5.84%↓

HLUNB.DK

44.1

+2.65%↑

ZEAL.DK

301.9

-3.08%↓

AMBUB.DK

64.45

-1.83%↓

NOVO.B.DK

277.8

-2.22%↓

GMAB.DK

1,540.5

-5.84%↓

HLUNB.DK

44.1

+2.65%↑

ZEAL.DK

301.9

-3.08%↓

AMBUB.DK

64.45

-1.83%↓

Kodu・Aktsiate loetelu・Coloplast A-S (Class B)

Coloplast A-S (Class B)

Avatud

376.5 -1.41

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

375.8

Max

384.9

Põhinäitajad
By Trading Economics
Sissetulek	-2.4B -971M
Müük	41M 7.1B
P/E Sektori keskmine	40.267 50.102
Aktsiakasum	-0.16
Dividenditootlus	6.02
Kasumimarginaal	-13.707
Töötajad	17,083
EBITDA	2.8B 5.1B

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+11.86% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	6.02% 2.33%

Turustatistika
By TradingEconomics
Turukapital	-5.3B 85B
Eelmine avamishind	377.91
Eelmine sulgemishind	376.5

Coloplast A-S (Class B) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. juuni 2026, 20:30 UTC

Tulu

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2. juuni 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2. juuni 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2. juuni 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2. juuni 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2. juuni 2026, 23:01 UTC

Omandamised, ülevõtmised, äriostud

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2. juuni 2026, 23:01 UTC

Omandamised, ülevõtmised, äriostud

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2. juuni 2026, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2. juuni 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2. juuni 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2. juuni 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. juuni 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2. juuni 2026, 21:00 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2. juuni 2026, 20:46 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:38 UTC

Tulu

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2. juuni 2026, 20:21 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:12 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Product Rev $594M

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Adj EPS 85c >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Loss $177M >PANW

Võrdlus sarnastega

Hinnamuutus

Coloplast A-S (Class B) Prognoos

Hinnasiht

By TipRanks

11.86% tõus

12 kuu keskmine prognoos

Keskmine 901.38 DKK 11.86%

Kõrge 1,056 DKK

Madal 720 DKK

Põhineb 8 Wall Streeti analüütiku instrumendi Coloplast A-S (Class B) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Coloplast A-S (Class B) aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.